Evrysdi Use Extended to Infants Younger Than 2 Months With Spinal Muscular Atrophy
The Food and Drug Administration (FDA) has expanded the approval of Evrysdi® (risdiplam) to include infants less than 2 months of age with spinal muscular atrophy (SMA). Previously, the treatment was only approved for patients 2…